JP2018524005A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524005A5 JP2018524005A5 JP2018500911A JP2018500911A JP2018524005A5 JP 2018524005 A5 JP2018524005 A5 JP 2018524005A5 JP 2018500911 A JP2018500911 A JP 2018500911A JP 2018500911 A JP2018500911 A JP 2018500911A JP 2018524005 A5 JP2018524005 A5 JP 2018524005A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fragment
- amino acid
- residues
- homology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 145
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 121
- 230000004927 fusion Effects 0.000 claims description 117
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 116
- 229920001184 polypeptide Polymers 0.000 claims description 112
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 112
- 102100035323 Fibroblast growth factor 18 Human genes 0.000 claims description 107
- 101000878128 Homo sapiens Fibroblast growth factor 18 Proteins 0.000 claims description 107
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 99
- 230000001747 exhibiting effect Effects 0.000 claims description 65
- 210000004027 cell Anatomy 0.000 claims description 14
- 108091008794 FGF receptors Proteins 0.000 claims description 13
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims description 13
- 125000000539 amino acid group Chemical group 0.000 claims description 10
- 210000001612 chondrocyte Anatomy 0.000 claims description 10
- 230000004048 modification Effects 0.000 claims description 9
- 238000012986 modification Methods 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 210000000845 cartilage Anatomy 0.000 claims description 7
- 230000012010 growth Effects 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 230000035755 proliferation Effects 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 230000010261 cell growth Effects 0.000 claims description 4
- 230000007547 defect Effects 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims description 2
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims description 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims description 2
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 102220313252 rs1386345719 Human genes 0.000 claims description 2
- 125000006850 spacer group Chemical group 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 206010061246 Intervertebral disc degeneration Diseases 0.000 description 1
- 208000013201 Stress fracture Diseases 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 208000018180 degenerative disc disease Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000021600 intervertebral disc degenerative disease Diseases 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2015/084133 | 2015-07-15 | ||
| CNPCT/CN2015/084133 | 2015-07-15 | ||
| PCT/CN2016/090110 WO2017008758A1 (en) | 2015-07-15 | 2016-07-15 | Fusion polypeptides and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018524005A JP2018524005A (ja) | 2018-08-30 |
| JP2018524005A5 true JP2018524005A5 (enExample) | 2019-08-15 |
| JP6951318B2 JP6951318B2 (ja) | 2021-10-20 |
Family
ID=57756671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018500911A Active JP6951318B2 (ja) | 2015-07-15 | 2016-07-15 | 融合ポリペプチドおよび使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11020454B2 (enExample) |
| EP (2) | EP3322736B1 (enExample) |
| JP (1) | JP6951318B2 (enExample) |
| CN (1) | CN107849151B (enExample) |
| WO (1) | WO2017008758A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3322736B1 (en) | 2015-07-15 | 2021-09-01 | Prosit Sole Biotechnology (Beijing) Co., Ltd | Fusion polypeptides and methods of use |
| US20180065317A1 (en) | 2016-09-06 | 2018-03-08 | Cc3D Llc | Additive manufacturing system having in-situ fiber splicing |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| GB8822228D0 (en) | 1988-09-21 | 1988-10-26 | Southern E M | Support-bound oligonucleotides |
| US5728546A (en) * | 1995-06-05 | 1998-03-17 | Human Genome Sciences, Inc. | Fibroblast growth factor 13 |
| IL129379A (en) | 1996-10-16 | 2008-12-29 | Zymogenetics Inc | Fibroblast growth factor homologues |
| DE69833755T2 (de) | 1997-05-21 | 2006-12-28 | Biovation Ltd. | Verfahren zur herstellung von nicht-immunogenen proteinen |
| GB9815157D0 (en) | 1998-07-13 | 1998-09-09 | Metron Designs Ltd | High resolution pulse width setting from relatively low frequency clocks |
| US7470665B2 (en) * | 1999-12-02 | 2008-12-30 | Zymogenetics, Inc. | Methods for targeting cells that express fibroblast growth receptor-3 or -2 |
| IL139380A0 (en) * | 2000-10-31 | 2001-11-25 | Prochon Biotech Ltd | Active variants of fibroblast growth factor |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| US7414019B2 (en) * | 2002-10-04 | 2008-08-19 | Auckland Uniservices Limited | FGF-8 methods of use |
| PL1828239T3 (pl) * | 2004-12-10 | 2012-01-31 | Zymogenetics Inc | Produkcja FGF18 w organizmach prokariotycznych |
| EP1990056A4 (en) | 2006-02-28 | 2010-02-24 | Nat Univ Corp Tokyo Med & Dent | DEVICE AND METHOD FOR THE PROMOTION OF DENTAL FORMATION |
| CA2658511C (en) | 2006-08-25 | 2019-02-19 | Ares Trading S.A. | Use of fgf-18 compound to treat cartilage disorders |
| ZA200900426B (en) | 2006-08-25 | 2010-04-28 | Ares Trading Sa | Treatment of cartilage disorders with FGF-18 |
| US20100286042A1 (en) * | 2007-10-12 | 2010-11-11 | National Institute Of Advanced Industrial Science And Technology | Medicinal Composition Containing Highly Functionalized Chimeric Protein |
| JP6016636B2 (ja) | 2009-10-15 | 2016-10-26 | ジェネンテック， インコーポレイテッド | 改変したレセプター特異性を持つキメラ線維芽細胞増殖因子 |
| WO2012038953A2 (en) * | 2010-09-21 | 2012-03-29 | Hepacore Ltd. | Fgf-18 truncated variants having increased receptor specificity and uses thereof |
| PL2726511T3 (pl) | 2011-07-01 | 2019-12-31 | Ngm Biopharmaceuticals, Inc. | Kompozycje, zastosowania i sposoby leczenia zaburzeń oraz chorób metabolicznych |
| PT2864360T (pt) * | 2012-06-25 | 2018-01-05 | The Brigham And Women`S Hospital Inc | Terapêuticas dirigidas ao alvo |
| EP3322736B1 (en) | 2015-07-15 | 2021-09-01 | Prosit Sole Biotechnology (Beijing) Co., Ltd | Fusion polypeptides and methods of use |
-
2016
- 2016-07-15 EP EP16823905.1A patent/EP3322736B1/en active Active
- 2016-07-15 EP EP21184080.6A patent/EP3957654A1/en not_active Withdrawn
- 2016-07-15 CN CN201680041325.1A patent/CN107849151B/zh active Active
- 2016-07-15 WO PCT/CN2016/090110 patent/WO2017008758A1/en not_active Ceased
- 2016-07-15 JP JP2018500911A patent/JP6951318B2/ja active Active
- 2016-07-15 US US15/744,712 patent/US11020454B2/en active Active
-
2021
- 2021-04-26 US US17/240,218 patent/US20210322516A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2011003121A1 (es) | Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso. | |
| TWI580692B (zh) | 經修飾纖維黏連蛋白片段或變體及其用途 | |
| FI3248610T3 (fi) | Fgf21-mutantit ja niiden käyttö | |
| EP2800759B1 (en) | Binding agents to intracellular target molecules | |
| EP2536757A1 (en) | Fibronectin based scaffold domain proteins that bind il-23 | |
| MXPA02001139A (es) | Polipeptidos quimericos, metodos para su produccion y usos de los mismos. | |
| AU2016268403A1 (en) | Pegylated interleukin-10 for use in treating cancer | |
| RU2010122053A (ru) | Иммуносупрессорные полипептиды и нуклеиновые кислоты | |
| CN104508129A (zh) | 设计的与血小板衍生生长因子结合的锚蛋白重复序列蛋白 | |
| BRPI0717441A2 (pt) | Composto, medicamento, e, uso do derivado de metastina | |
| CA2590512A1 (en) | Fusion protein comprising a bh3-domain of a bh3-only protein | |
| Kanematsu-Yamaki et al. | Potent body weight-lowering effect of a neuromedin U receptor 2-selective PEGylated peptide | |
| JP5992529B2 (ja) | ポリペプチド、足場組成物、軟骨組織修復用組成物、軟骨細胞培養用組成物及びグリコサミノグリカン産生促進用組成物 | |
| JP2018524005A5 (enExample) | ||
| AU2016252008B2 (en) | Polypeptides targeting HIV fusion | |
| EP2909233B1 (en) | Polypeptides capable of cellular internalization | |
| CN103965295B (zh) | BLyS拮抗肽、含TA-Fc融合蛋白基因的质粒及TA-Fc融合蛋白 | |
| CN107849151B (zh) | 融合多肽及使用方法 | |
| US20230357323A1 (en) | Human il23 receptor binding polypeptides | |
| AU2019408420B2 (en) | Fusion protein with a toxin and scaffold protein | |
| WO2014071234A1 (en) | Gb1 peptidic compounds and methods for making and using the same | |
| JP7602486B2 (ja) | リジルオキシダーゼのペプチドを含む組成物及びその使用 | |
| JP2024518125A (ja) | 組織再生の促進に有用なｈｍｇｂ１関連ポリペプチド、それを含む組成物及びその使用 | |
| Quan et al. | Versatile triblock peptides mimicking ABC-type heterotrimeric collagen with stabilizing salt bridges | |
| US20250223336A1 (en) | Therapeutic miniprotein mimics and a process of producing the same |